Does the media refer more to TNDM or CARL?

In the previous week, Tandem Diabetes Care and Tandem Diabetes Care both had 10 articles in the media. Tandem Diabetes Care's average media sentiment score of 1.35 beat Carlsmed's score of 0.44 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Carlsmed 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CARL or AVNS?

Carlsmed presently has a consensus target price of $18.75, suggesting a potential upside of 38.27%. Given Carlsmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Carlsmed is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carlsmed 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is CARL or AVNS more profitable?

Avanos Medical has a net margin of -10.39% compared to Carlsmed's net margin of -57.76%. Avanos Medical's return on equity of 5.39% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets Carlsmed -57.76% -60.74% -29.84% Avanos Medical -10.39% 5.39% 3.97%

Does the media favor CARL or AVNS?

In the previous week, Carlsmed had 7 more articles in the media than Avanos Medical. MarketBeat recorded 10 mentions for Carlsmed and 3 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 0.81 beat Carlsmed's score of 0.44 indicating that Avanos Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avanos Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CARL or DRTS?

In the previous week, Carlsmed had 5 more articles in the media than Alpha Tau Medical. MarketBeat recorded 10 mentions for Carlsmed and 5 mentions for Alpha Tau Medical. Alpha Tau Medical's average media sentiment score of 0.54 beat Carlsmed's score of 0.44 indicating that Alpha Tau Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Tau Medical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, BVS or CARL?

Bioventus has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 2.24 $22.73M $0.41 37.22 Carlsmed $50.51M 7.30 -$29.63M -$2.51 N/A

Is BVS or CARL more profitable?

Bioventus has a net margin of 4.94% compared to Carlsmed's net margin of -57.76%. Bioventus' return on equity of 29.97% beat Carlsmed's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% Carlsmed -57.76% -60.74% -29.84%

Does the media prefer BVS or CARL?

In the previous week, Bioventus had 3 more articles in the media than Carlsmed. MarketBeat recorded 13 mentions for Bioventus and 10 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.44 beat Bioventus' score of 0.33 indicating that Carlsmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Carlsmed 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CARL or PRCT?

In the previous week, PROCEPT BioRobotics had 45 more articles in the media than Carlsmed. MarketBeat recorded 55 mentions for PROCEPT BioRobotics and 10 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.44 beat PROCEPT BioRobotics' score of -0.01 indicating that Carlsmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carlsmed 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PROCEPT BioRobotics 5 Very Positive mention(s) 3 Positive mention(s) 39 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral

Carlsmed (CARL) Competitors

$13.56 +0.13 (+0.97%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$13.75 +0.19 (+1.40%)

As of 08/5/2026 07:55 PM Eastern

Compare

CARL vs. TNDM, AVNS, DRTS, BVS, and PRCT

Should you buy Carlsmed stock or one of its competitors? MarketBeat compares Carlsmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Carlsmed include Tandem Diabetes Care (TNDM), Avanos Medical (AVNS), Alpha Tau Medical (DRTS), Bioventus (BVS), and PROCEPT BioRobotics (PRCT).

How does Carlsmed compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Carlsmed (NASDAQ:CARL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Carlsmed has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.32	-$204.71M	-$1.40	N/A
Carlsmed	$50.51M	7.30	-$29.63M	-$2.51	N/A

Tandem Diabetes Care has a net margin of -9.20% compared to Carlsmed's net margin of -57.76%. Tandem Diabetes Care's return on equity of -53.88% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
Carlsmed	-57.76%	-60.74%	-29.84%

Tandem Diabetes Care presently has a consensus price target of $28.73, suggesting a potential upside of 46.63%. Carlsmed has a consensus price target of $18.75, suggesting a potential upside of 38.27%. Given Tandem Diabetes Care's higher possible upside, equities research analysts clearly believe Tandem Diabetes Care is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.45
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Tandem Diabetes Care and Tandem Diabetes Care both had 10 articles in the media. Tandem Diabetes Care's average media sentiment score of 1.35 beat Carlsmed's score of 0.44 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Carlsmed	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tandem Diabetes Care beats Carlsmed on 9 of the 13 factors compared between the two stocks.

How does Carlsmed compare to Avanos Medical?

Carlsmed (NASDAQ:CARL) and Avanos Medical (NYSE:AVNS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Avanos Medical has a net margin of -10.39% compared to Carlsmed's net margin of -57.76%. Avanos Medical's return on equity of 5.39% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Avanos Medical	-10.39%	5.39%	3.97%

In the previous week, Carlsmed had 7 more articles in the media than Avanos Medical. MarketBeat recorded 10 mentions for Carlsmed and 3 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 0.81 beat Carlsmed's score of 0.44 indicating that Avanos Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avanos Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.2% of Avanos Medical shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by company insiders. Comparatively, 2.3% of Avanos Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Carlsmed has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	7.30	-$29.63M	-$2.51	N/A
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A

Carlsmed presently has a consensus target price of $18.75, suggesting a potential upside of 38.27%. Given Carlsmed's stronger consensus rating and higher possible upside, equities analysts plainly believe Carlsmed is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Carlsmed beats Avanos Medical on 8 of the 15 factors compared between the two stocks.

How does Carlsmed compare to Alpha Tau Medical?

Carlsmed (NASDAQ:CARL) and Alpha Tau Medical (NASDAQ:DRTS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Alpha Tau Medical has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Alpha Tau Medical	N/A	-73.23%	-52.90%

2.7% of Alpha Tau Medical shares are owned by institutional investors. 12.9% of Carlsmed shares are owned by insiders. Comparatively, 39.5% of Alpha Tau Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Carlsmed currently has a consensus price target of $18.75, indicating a potential upside of 38.27%. Alpha Tau Medical has a consensus price target of $12.60, indicating a potential downside of 4.98%. Given Carlsmed's higher possible upside, equities analysts plainly believe Carlsmed is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Carlsmed has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	7.30	-$29.63M	-$2.51	N/A
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.67	N/A

In the previous week, Carlsmed had 5 more articles in the media than Alpha Tau Medical. MarketBeat recorded 10 mentions for Carlsmed and 5 mentions for Alpha Tau Medical. Alpha Tau Medical's average media sentiment score of 0.54 beat Carlsmed's score of 0.44 indicating that Alpha Tau Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Tau Medical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Carlsmed beats Alpha Tau Medical on 7 of the 13 factors compared between the two stocks.

How does Carlsmed compare to Bioventus?

Bioventus (NASDAQ:BVS) and Carlsmed (NASDAQ:CARL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Bioventus has a net margin of 4.94% compared to Carlsmed's net margin of -57.76%. Bioventus' return on equity of 29.97% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Carlsmed	-57.76%	-60.74%	-29.84%

Bioventus has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	2.24	$22.73M	$0.41	37.22
Carlsmed	$50.51M	7.30	-$29.63M	-$2.51	N/A

62.9% of Bioventus shares are held by institutional investors. 33.5% of Bioventus shares are held by insiders. Comparatively, 12.9% of Carlsmed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bioventus currently has a consensus target price of $14.75, indicating a potential downside of 3.34%. Carlsmed has a consensus target price of $18.75, indicating a potential upside of 38.27%. Given Carlsmed's higher possible upside, analysts clearly believe Carlsmed is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Bioventus had 3 more articles in the media than Carlsmed. MarketBeat recorded 13 mentions for Bioventus and 10 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.44 beat Bioventus' score of 0.33 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Carlsmed	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bioventus beats Carlsmed on 12 of the 15 factors compared between the two stocks.

How does Carlsmed compare to PROCEPT BioRobotics?

Carlsmed (NASDAQ:CARL) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, PROCEPT BioRobotics had 45 more articles in the media than Carlsmed. MarketBeat recorded 55 mentions for PROCEPT BioRobotics and 10 mentions for Carlsmed. Carlsmed's average media sentiment score of 0.44 beat PROCEPT BioRobotics' score of -0.01 indicating that Carlsmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Carlsmed	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PROCEPT BioRobotics	5 Very Positive mention(s)	3 Positive mention(s)	39 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

PROCEPT BioRobotics has a net margin of -32.53% compared to Carlsmed's net margin of -57.76%. PROCEPT BioRobotics' return on equity of -30.10% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
PROCEPT BioRobotics	-32.53%	-30.10%	-21.85%

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 12.9% of Carlsmed shares are held by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Carlsmed presently has a consensus target price of $18.75, suggesting a potential upside of 38.27%. PROCEPT BioRobotics has a consensus target price of $28.00, suggesting a potential upside of 44.78%. Given PROCEPT BioRobotics' higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
PROCEPT BioRobotics	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.19

Carlsmed has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	7.30	-$29.63M	-$2.51	N/A
PROCEPT BioRobotics	$308.05M	3.57	-$95.57M	-$1.82	N/A

Summary

PROCEPT BioRobotics beats Carlsmed on 9 of the 16 factors compared between the two stocks.

Get Carlsmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARL vs. The Competition

Export

Metric	Carlsmed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$365.09M	$5.82B	$6.87B	$12.98B
Dividend Yield	N/A	1.78%	2.60%	9.79%
P/E Ratio	-5.40	23.49	280.35	25.25
Price / Sales	7.30	58.67	604.25	94.30
Price / Cash	N/A	32.67	71.79	50.79
Price / Book	3.65	6.12	12.97	6.09
Net Income	-$29.63M	$151.74M	$3.49B	$347.95M
7 Day Performance	7.11%	3.51%	2.41%	3.11%
1 Month Performance	10.33%	-1.63%	-2.87%	-2.99%
1 Year Performance	N/A	8.95%	75.29%	20.51%

Carlsmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARL Carlsmed	2.1214 of 5 stars	$13.56 +1.0%	$18.75 +38.3%	N/A	$365.09M	$50.51M	N/A	100	News Coverage Earnings Report
TNDM Tandem Diabetes Care	2.849 of 5 stars	$17.12 +1.3%	$28.93 +69.0%	+29.3%	$1.17B	$1.01B	N/A	2,500	Positive News Options Volume Gap Down
AVNS Avanos Medical	1.1428 of 5 stars	$25.00 +0.1%	N/A	N/A	$1.17B	$701.20M	N/A	2,287	Upcoming Earnings High Trading Volume
DRTS Alpha Tau Medical	1.5023 of 5 stars	$12.50 -5.6%	$12.60 +0.8%	+331.9%	$1.13B	N/A	N/A	80	Upcoming Earnings Analyst Upgrade
BVS Bioventus	2.8931 of 5 stars	$11.80 +2.8%	$14.75 +25.0%	+148.5%	$985.71M	$568.09M	28.78	1,200	Trending News Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARL) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carlsmed (CARL) Competitors

CARL vs. TNDM, AVNS, DRTS, BVS, and PRCT

How does Carlsmed compare to Tandem Diabetes Care?

Summary

How does Carlsmed compare to Avanos Medical?

Summary

How does Carlsmed compare to Alpha Tau Medical?

Summary

How does Carlsmed compare to Bioventus?

Summary

How does Carlsmed compare to PROCEPT BioRobotics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARL vs. The Competition

Carlsmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carlsmed (CARL) Competitors

CARL vs. TNDM, AVNS, DRTS, BVS, and PRCT

How does Carlsmed compare to Tandem Diabetes Care?

Which has better valuation & earnings, TNDM or CARL?

Is TNDM or CARL more profitable?

Do analysts prefer TNDM or CARL?

Does the media refer more to TNDM or CARL?

Summary

How does Carlsmed compare to Avanos Medical?

Is CARL or AVNS more profitable?

Does the media favor CARL or AVNS?

Do institutionals & insiders hold more shares of CARL or AVNS?

Which has better valuation and earnings, CARL or AVNS?

Do analysts recommend CARL or AVNS?

Summary

How does Carlsmed compare to Alpha Tau Medical?

Is CARL or DRTS more profitable?

Do institutionals & insiders believe in CARL or DRTS?

Do analysts recommend CARL or DRTS?

Which has higher valuation and earnings, CARL or DRTS?

Does the media prefer CARL or DRTS?

Summary

How does Carlsmed compare to Bioventus?

Is BVS or CARL more profitable?

Which has preferable valuation and earnings, BVS or CARL?

Do institutionals & insiders have more ownership in BVS or CARL?

Do analysts prefer BVS or CARL?

Does the media prefer BVS or CARL?

Summary

How does Carlsmed compare to PROCEPT BioRobotics?

Does the media prefer CARL or PRCT?

Is CARL or PRCT more profitable?

Do institutionals and insiders believe in CARL or PRCT?

Do analysts prefer CARL or PRCT?

Which has preferable valuation & earnings, CARL or PRCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARL vs. The Competition

Carlsmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools